MPI and OV announces registration of trademark for DRP
Hoersholm, Denmark – November 1st 2017 – Oncology Venture Sweden AB:s (OV:ST) and Medical Prognosis Institute A/S (MPI.ST) today informed that the United States Patent & Trademark Office (USTPO) has allowed and registered its primary trademark, DRP®, used in connection with the Company’s core predictive biomarker platform and services. The DRP® biomarker platform uses tumor mRNA and proprietary analytics to develop tumor-derived genetic signatures, which are used to identify which cancer patients are likely to respond to a given anti-cancer drug. This proprietary technology has been